Market Research Report Non-Small Cell Lung Cancer Therapeutics Market

Non-Small Cell Lung Cancer Therapeutics in Asia-
Pacific Markets Trends and Research Report 2023
Market Research Hub (MRH) has recently announced the addition of a fresh report,
titled “Non-Small Cell Lung Cancer Therapeutics in Asia-Pacific Markets to 2023 -
Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the
Market” to its report offerings. The report visualize the composition of the NSCLC
market in terms of dominant therapies for each patient subset along with their clinical
and commercial standing. Unmet needs are highlighted to allow a competitive
understanding of gaps in the current market.
Request Free Sample Report:
http://www.marketresearchhub.com/enquiry.php?type=S&repid=1049126
Non-Small Cell Lung Cancer (NSCLC) is the most common cancer and the leading
cause of cancer-related mortality globally. There were more than 1.8 million newly
diagnosed lung cancer cases in 2012, accounting for 13% of the total number of
cancer cases. This figure has been gradually rising with increased smoking and the
growing elderly population. Lung cancer is a leading cause of death worldwide,
accounting for 1.69 million deaths in 2015. Over half of the incident cases of NSCLC
are diagnosed in patients over the age of 65 a high-risk age range for lung cancer.
As the aged population is projected to grow, the prevalence of lung cancer is
anticipated to increase, acting as a driver for revenue growth.
The poor prognosis, particularly for patients with advanced disease, has created a
pressing need for improved therapeutic options. The NSCLC market is therefore
shifting from a focus on generic chemotherapy regimens to a complex treatment
landscape based on different NSCLC subtypes, and the presence of various
molecular aberrations.